Comparative Pharmacology
Head-to-head clinical analysis: AFRINOL versus NOVAFED.
Peer-Reviewed Evidence
Head-to-head clinical analysis: AFRINOL versus NOVAFED.
AFRINOL vs NOVAFED
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Afrinol is a sympathomimetic amine that acts as a nasal decongestant by stimulating alpha-1 adrenergic receptors in the vascular smooth muscle of nasal blood vessels, causing vasoconstriction and reducing nasal congestion. It also has weak alpha-2 agonist activity.
Novafed contains pseudoephedrine, a sympathomimetic amine that acts as a decongestant by stimulating alpha-adrenergic receptors in the respiratory tract mucosa, causing vasoconstriction and reducing nasal congestion.
Oral: 1 tablet (pseudoephedrine 120 mg, triprolidine 2.5 mg) every 12 hours; maximum 2 tablets per day.
1-2 capsules orally every 12 hours; each capsule contains pseudoephedrine HCl 120 mg and dextromethorphan HBr 30 mg.
None Documented
None Documented
9–11 hours in healthy adults; prolonged to 16–18 hours in hepatic cirrhosis and up to 20 hours in severe renal impairment. Clinical context: dosing interval typically 12 hours in normal renal function.
Terminal elimination half-life: 4-8 hours (mean 5-6 hours); prolonged in renal impairment (up to 20 hours) and with urinary alkalinization; in patients with normal renal function, steady-state is achieved after 2-3 days of every-6-hour dosing.
Renal (approximately 70–90% as unchanged drug and metabolites), with about 10% biliary/fecal elimination. Dose adjustment required in renal impairment (CrCl <30 mL/min).
Renal elimination of unchanged drug and metabolites; approximately 60-70% of a dose is excreted in urine as unchanged pseudoephedrine within 24 hours; the remainder is metabolized hepatically and excreted renally; minimal biliary/fecal elimination (<5%).
Category C
Category C
Decongestant
Decongestant